Key result
Long noncoding RNAs may play a regulatory role in beta-cell identity and Type 2 Diabetes susceptibility, serving as potential novel diagnostic biomarkers.
Why the study?
As increasing numbers of lncRNAs are identified in β cells, understanding their regulatory roles in T2D is needed to inform the development of novel diagnostic biomarkers.
Long noncoding RNAs may serve as novel diagnostic biomarkers for Type 2 Diabetes by reflecting β-cell identity and disease susceptibility.
Hypothesis-generating for lncRNA diagnostics in T2D; prospective validation required before clinical adoption.
Type 2 diabetes (T2D) is a metabolic disease characterized by disordered glucagon secretion, insulin resistance in target tissues, and decreased islet β-cell mass and function. The routine diagnosis was based on measurements of metabolic markers, while genetic risk factors have been considered to increase the probability of predicting the development of the disease. Recent evidence suggests that long noncoding RNAs (lncRNAs) regulate gene expression in various physiological and pathological processes. As increasing lncRNAs are identified in β cells, understanding the regulatory roles of lncRNAs in T2D becomes indispensable. In this review, we discuss the potential role of lncRNAs contributing to β-cell identity and T2D susceptibility, which provide a perspective insight into the development of novel diagnosis biomarkers for T2D.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) conducted a review in Type 2 Diabetes. Long noncoding RNAs (lncRNAs) was evaluated. Long noncoding RNAs may play a regulatory role in beta-cell identity and Type 2 Diabetes susceptibility, serving as potential novel diagnostic biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: